{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:17:06Z","timestamp":1789777026484,"version":"4.0.1"},"reference-count":95,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist approved for treating Alzheimer\u2019s disease, has a good safety profile and is increasingly being studied for possible use in a variety of non-dementia psychiatric disorders. There is an abundance of basic and clinical data that support the hypothesis that NMDA receptor hypofunction contributes to the pathophysiology of schizophrenia. However, there are numerous randomized, double-blind, placebo-controlled clinical trials showing that add-on treatment with memantine improves negative and cognitive symptoms, particularly the negative symptoms of schizophrenia, indicating that memantine as adjunctive therapy in schizophrenia helps to ameliorate negative symptoms and cognitive deficits. It remains unclear why memantine does not show undesirable central nervous system (CNS) side effects in humans unlike other NMDA receptor antagonists, such as phencyclidine and ketamine. However, the answer could lie in the fact that it would appear that memantine works as a low-affinity, fast off-rate, voltage-dependent, and uncompetitive antagonist with preferential inhibition of extrasynaptic receptors. It is reasonable to assume that the effects of memantine as adjunctive therapy on negative symptoms and cognitive deficits in schizophrenia may derive primarily, if not totally, from its NMDA receptor antagonist activity at NMDA receptors including extrasynaptic receptors in the CNS.<\/jats:p>","DOI":"10.3390\/biom10081134","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T06:16:47Z","timestamp":1596435407000},"page":"1134","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?"],"prefix":"10.3390","volume":"10","author":[{"given":"Tetsuro","family":"Kikuchi","sequence":"first","affiliation":[{"name":"New Drug Research Division, Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima 771-0192, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1568007024606221","article-title":"Current status of antipsychotic treatment","volume":"37","author":"Conley","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yang, A.C., and Tsai, S.-J. (2017). New target for schizophrenia treatment beyond the dopamine hypothesis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081689"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.mcna.2018.10.009","article-title":"The Alzheimer\u2019s disease clinical spectrum: Diagnosis and management","volume":"103","author":"Atri","year":"2019","journal-title":"Med. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/bs.apha.2016.01.006","article-title":"The NMDA receptor and schizophrenia: From pathophysiology to treatment","volume":"76","author":"Balu","year":"2016","journal-title":"Adv. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans","volume":"51","author":"Kristal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/00001756-199504190-00011","article-title":"Ketamine activates psychosis and alters limbic blood flow in schizophrenia","volume":"6","author":"Lahti","year":"1995","journal-title":"Neuroreport"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenia","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.1073\/pnas.83.18.7104","article-title":"The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist","volume":"83","author":"Wong","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/026988119200600312","article-title":"Chemical dissociation of human awareness: Focus on non-competitive NMDA receptor antagonists","volume":"6","author":"Domino","year":"1992","journal-title":"J. Psychopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10673229609017192","article-title":"The glutamatergic dysfunction hypothesis for schizophrenia","volume":"3","author":"Coyle","year":"1996","journal-title":"Harv. Rev. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.schres.2019.03.010","article-title":"NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms","volume":"217","author":"Snyder","year":"2020","journal-title":"Schizophr. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107426","DOI":"10.1016\/j.pharmthera.2019.107426","article-title":"The origin of NMDA receptor hypofunction in schizophrenia","volume":"205","author":"Nakazawa","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.12547","article-title":"The glutamate hypothesis of schizophrenia: Evidence from human brain tissue studies","volume":"1338","author":"Hu","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/sj.mp.4001751","article-title":"First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients","volume":"11","author":"Pilowsky","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/mp.2013.136","article-title":"Imaging glutamate in schizophrenia: Review of findings and implications for drug discovery","volume":"19","author":"Poels","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(03)12379-3","article-title":"Genes for schizophrenia? Recent findings and their pathophysiological implications","volume":"361","author":"Harrison","year":"2003","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2174\/138161212799958594","article-title":"Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia","volume":"18","author":"Schwartz","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.schres.2014.10.007","article-title":"Anti-NMDA receptor encephalitis, autoimmunity, and psychosis","volume":"176","author":"Kayser","year":"2016","journal-title":"Schizophr. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tins.2015.06.002","article-title":"Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment","volume":"38","author":"Ellaithy","year":"2015","journal-title":"Trends Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14728222.2014.934225","article-title":"Targeting of NMDA receptors in new treatments for schizophrenia","volume":"18","author":"Hashimoto","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jpsychires.2013.04.013","article-title":"NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials","volume":"47","author":"Kishi","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/JCP.0b013e31828b50a7","article-title":"Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized, double-blind, placebo-controlled study","volume":"33","author":"Rezaei","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.jpsychires.2013.09.002","article-title":"Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials","volume":"47","author":"Matsuda","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00213-017-4616-7","article-title":"Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: A meta-analysis","volume":"234","author":"Kishi","year":"2017","journal-title":"Psychopharmacology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Di Iorio, G., Baroni, G., Lorusso, M., Montemitro, C., Spano, M.C., and di Giannantonio, M. (2017). Efficacy of memantine in schizophrenic patients: A systematic review. J. Amino Acids, 7021071.","DOI":"10.1155\/2017\/7021071"},{"key":"ref_29","first-page":"696","article-title":"Memantine enhances the effect of olanzapine in patients with schizophrenia: A randomized, placebo-controlled study","volume":"54","author":"Fakhri","year":"2016","journal-title":"Acta Med. Iran."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.psychres.2016.09.028","article-title":"Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial","volume":"247","author":"Mazinani","year":"2017","journal-title":"Psychiatry Res."},{"key":"ref_31","first-page":"107","article-title":"The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: A double-blind, randomized, controlled trial","volume":"45","author":"Omranifard","year":"2017","journal-title":"Actas Esp. Psiquiatr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/JCP.0000000000001115","article-title":"Adjunctive memantine treatment of schizophrenia: A double-blind, randomized placebo-controlled study","volume":"39","author":"Hassanpour","year":"2019","journal-title":"J Clin. Psychopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1017\/S0033291717001271","article-title":"Adjunctive memantine for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"48","author":"Zheng","year":"2018","journal-title":"Psychol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2019.05.019","article-title":"Adjunctive memantine for major mental disorders; A systematic review and meta-analysis of randomized double-blind controlled trials","volume":"209","author":"Zheng","year":"2019","journal-title":"Schizophr. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/a-0970-9310","article-title":"Acute and long-term memantine add-on treatment to risperidone improves cognitive dysfunction in patients with acute and chronic schizophrenia","volume":"53","author":"Schaefer","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1017\/S1461145708009085","article-title":"Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: Association with N-methyl-D-aspartic acid receptor up-regulation","volume":"12","author":"Gray","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2012.02.033","article-title":"Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia","volume":"682","author":"Sarappa","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.08m04935gry","article-title":"Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine","volume":"70","author":"Fernandes","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1017\/S0033291716000398","article-title":"Memantine augmentation in clozapine-refractory schizophrenia: A randomized, double-blind, placebo-controlled crossover study","volume":"46","author":"Veerman","year":"2016","journal-title":"Psychol. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1017\/S0033291716002476","article-title":"Adjunctive memantine in clozapine-treated refractory schizophrenia: An open-label 1-year extension study","volume":"47","author":"Veerman","year":"2017","journal-title":"Psychol. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/2277-9175.166148","article-title":"The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, double-blind, controlled, clinical trial","volume":"4","author":"Omranifard","year":"2015","journal-title":"Adv. Biomed. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: A meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs"},{"key":"ref_44","first-page":"234","article-title":"The use of memantine in neuropsychiatric disorders: An overview","volume":"30","author":"Lu","year":"2018","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/cmdc.201700810","article-title":"Comparative pharmacological study of common NMDA receptor open channel blockers regarding their affinity and functional activity toward GluN2A and GluN2B NMDA receptors","volume":"13","author":"Temme","year":"2018","journal-title":"ChemMedChem"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2174\/156802606776894483","article-title":"Relationship between the structure of dexoxadrol and etoxadrol analogues and their NMDA receptor affinity","volume":"6","author":"Sax","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","article-title":"A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia","volume":"17","author":"Angus","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.01.016","article-title":"Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders","volume":"159","author":"Nguyen","year":"2016","journal-title":"Pharmacol. Therapeut."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","article-title":"Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist\u2014A review of preclinical data","volume":"38","author":"Parsons","year":"1999","journal-title":"Neuropharmacology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s007260070044","article-title":"Memantine and the amino-alkyl-cyclohexane MRZ 2\/579 are moderate affinity uncompetitive NMDA receptor antagonists\u2014In vitro characterization","volume":"19","author":"Parsons","year":"2000","journal-title":"Amino Acids"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00210-015-1085-6","article-title":"Potencies and unblocking kinetic properties of antagonists at recombinant human NMDA receptors in a Xenopus oocytes model","volume":"388","author":"Heusler","year":"2015","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrd1958","article-title":"Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond","volume":"5","author":"Lipton","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","article-title":"Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2014Too little activation is bad, too much is even worse","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157015908783769671","article-title":"Pharmacodynamics of memantine: An update","volume":"6","author":"Rammes","year":"2008","journal-title":"Curr. Neuropharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/jn.1997.77.1.309","article-title":"Tapping Channel block of NMDA-activated responses by amantadine and memantine","volume":"77","author":"Blanpied","year":"1997","journal-title":"J. Neurophysiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.3233\/JAD-2004-6S610","article-title":"Paradigm shift in NMDA receptor antagonist drug development: Molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer\u2019s disease and other neurologic disorders","volume":"6","author":"Lipton","year":"2004","journal-title":"J. Alzheimers Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1523\/JNEUROSCI.12-11-04427.1992","article-title":"Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity","volume":"12","author":"Chen","year":"1992","journal-title":"J. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1113\/jphysiol.1997.sp021909","article-title":"Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism","volume":"499","author":"Chen","year":"1997","journal-title":"J. Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.neuropharm.2009.01.012","article-title":"Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1\/GluN2A) receptors","volume":"56","author":"Gilling","year":"2009","journal-title":"Neuropharmacology"},{"key":"ref_61","first-page":"30","article-title":"Anticonvulsant activity of the low-affinity uncompetitive N-methyl-D-aspartate antagonist (\u00b1)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (ADCI): Comparison with the structural analogs dizocilpine (MK-801) and carbamazepine","volume":"259","author":"Rogawski","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0091-3057(94)90285-2","article-title":"Evaluation of ADCI against convulsant and locomotor stimulant effects of cocaine: Comparison with the structural analogs dizocilpine and carbamazepine","volume":"47","author":"Seidleck","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41586-018-0039-9","article-title":"Mechanism of NMDA receptor channel block by MK-801 and memantine","volume":"566","author":"Song","year":"2018","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuroscience.2008.05.029","article-title":"Surface trafficking of N-methyl-D-aspartate receptors: Physiological and pathological perspectives","volume":"158","author":"Groc","year":"2009","journal-title":"Neuroscience"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11246","DOI":"10.1523\/JNEUROSCI.2488-10.2010","article-title":"Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses","volume":"30","author":"Xia","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2015.01.041","article-title":"Memantine selectively blocks extrasynaptic NMDA receptors in rat substantia nigra dopamine neurons","volume":"1603","author":"Wu","year":"2015","journal-title":"Brain Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1523\/JNEUROSCI.4129-11.2012","article-title":"Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons","volume":"32","author":"Kaufman","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nm.2056","article-title":"Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin","volume":"15","author":"Okamoto","year":"2009","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1021\/acs.nanolett.6b01988","article-title":"Nanostructured antagonist of extrasynaptic NMDA receptors","volume":"16","author":"Savchenko","year":"2016","journal-title":"Nano Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.coph.2014.11.006","article-title":"Recent insights into the mode of action of memantine and ketamine","volume":"20","author":"Johnson","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/mol.111.073239","article-title":"Mechanism for noncompetitive inhibition by novel GluN2C\/D N-methyl-D-aspartate receptor subunit-selective modulators","volume":"80","author":"Acker","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5607\/en.2013.22.1.18","article-title":"Memantine reverses social withdrawal induced by ketamine in rats","volume":"22","author":"Uribe","year":"2013","journal-title":"Exp. Neurobiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neulet.2016.07.061","article-title":"Memantine, an NMDA receptor antagonist, improves working memory deficits in DGK\u03b2 knockout mice","volume":"630","author":"Kakefuda","year":"2016","journal-title":"Neurosci. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/WNR.0b013e32834d2ef7","article-title":"Phencyclidine treatment increases NR2A and NR2B N-methyl-D-aspartate receptor subunit expression in rats","volume":"22","author":"Owczarek","year":"2011","journal-title":"NeuroReport"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Hasegawa, T., and Okada, M. (2018). Cystine\/glutamate antiporter and aripiprazole compensate NMDA antagonist-induced dysfunction of thalamocortical L-glutamatergic transmission. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113645"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e00457","DOI":"10.1002\/prp2.457","article-title":"Memantine protects thalamocortical hyper-glutamatergic transmission induced by NMDA receptor antagonism via activation of system xc\u2212","volume":"7","author":"Okada","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1345\/aph.1G297","article-title":"Catatonic schizophrenia and the use of memantine","volume":"40","author":"Carpenter","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/01.pra.0000400268.60537.5e","article-title":"Memantine and Catatonia: A case report and literature review","volume":"17","author":"Obregon","year":"2011","journal-title":"J. Psychiatr. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.psym.2016.08.001","article-title":"Catatonia delirium: 3 cases treated with memantine","volume":"57","author":"Roy","year":"2016","journal-title":"Psychosomatics"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.schres.2015.07.029","article-title":"NMDA receptor blockade and catatonia: A complex relationship","volume":"168","author":"Inta","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/JCP.0000000000001145","article-title":"Memantine as adjunctive therapy in a patient with anti-N-methyl-D-aspartate receptor encephalitis","volume":"40","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biopsycho.2015.06.015","article-title":"Mismatch responses and deviance detection in N-methyl-D-aspartate (NMDA) receptor hypofunction and development models of schizophrenia","volume":"116","author":"Harms","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/npp.2015.162","article-title":"Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis","volume":"41","author":"Swerdlow","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Harms, L., Parras, G.G., Michie, P.T., and Malmierca, M.S. (2020). The role of glutamate neurotransmission in mismatch negativity (MMN), a measure of auditory synaptic plasticity and change-detection. Neuroscience, 32045628.","DOI":"10.1016\/j.neuroscience.2020.01.046"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.05.006","article-title":"MK-801 disrups and nicotine augments 40 Hz auditory steady state responses in the auditory cortex of the urethane-anesthetized rat","volume":"73","author":"Sivarao","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1038\/npp.2017.81","article-title":"Single-dose memantine improves cortical oscillatory response dynamics in patients with schizophrenia","volume":"42","author":"Light","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_87","first-page":"562","article-title":"Memantine effects on electroencephalographic measures of putative excitatory\/inhibitory balance in schizophrenia","volume":"5","author":"Molina","year":"2020","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1023\/A:1018856020583","article-title":"Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: A quantitative microdialysis study","volume":"16","author":"Hesselink","year":"1999","journal-title":"Pharm. Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Kornhuber, J., and Quack, G. (1995). Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett., 137\u2013139.","DOI":"10.1016\/0304-3940(95)11785-U"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e1307","DOI":"10.4088\/JCP.17f11998","article-title":"Memantine as an augmentation treatment for schizophrenia: Limitation of meta-analysis for evidence-based evaluation of research","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","article-title":"The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner","volume":"306","author":"Rammes","year":"2001","journal-title":"Neurosci. Lett."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2014.07.030","article-title":"Decreasing nicotinic receptor activity and the spatial learning impairment caused by the NMDA glutamate antagonist dizocilpine in rats","volume":"741","author":"Burke","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/sj.bjp.0705559","article-title":"Inhibition of human \u03b17 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors","volume":"140","author":"Maskell","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/syn.20472","article-title":"Memantine agonist action at dopamine D2High receptors","volume":"62","author":"Seeman","year":"2008","journal-title":"Synapse"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0893-133X(00)00194-9","article-title":"Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men: A randomized, double-blind, placebo-controlled trial","volume":"24","author":"Hergovich","year":"2001","journal-title":"Neuropsychopharmacology"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/8\/1134\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:53:22Z","timestamp":1760176402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/8\/1134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":95,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["biom10081134"],"URL":"https:\/\/doi.org\/10.3390\/biom10081134","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]}}}